- Home
- LDWY vs PPBT Comparison
LDWY vs PPBT Comparison
Compare LDWY & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- PPBT
- Stock Information
- Founded
- LDWY 1990
- PPBT 2010
- Country
- LDWY United States
- PPBT Israel
- Employees
- LDWY N/A
- PPBT N/A
- Industry
- LDWY Advertising
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- PPBT Health Care
- Exchange
- LDWY Nasdaq
- PPBT Nasdaq
- Market Cap
- LDWY 8.9M
- PPBT 5.5M
- IPO Year
- LDWY 1991
- PPBT N/A
- Fundamental
- Price
- LDWY N/A
- PPBT $0.61
- Analyst Decision
- LDWY
- PPBT Strong Buy
- Analyst Count
- LDWY 0
- PPBT 1
- Target Price
- LDWY N/A
- PPBT $33.00
- AVG Volume (30 Days)
- LDWY 1.4K
- PPBT 256.2K
- Earning Date
- LDWY 11-18-2025
- PPBT 11-14-2025
- Dividend Yield
- LDWY N/A
- PPBT N/A
- EPS Growth
- LDWY N/A
- PPBT N/A
- EPS
- LDWY 1.66
- PPBT N/A
- Revenue
- LDWY $71,244,000.00
- PPBT N/A
- Revenue This Year
- LDWY N/A
- PPBT N/A
- Revenue Next Year
- LDWY N/A
- PPBT N/A
- P/E Ratio
- LDWY $3.11
- PPBT N/A
- Revenue Growth
- LDWY 187.12
- PPBT N/A
- 52 Week Low
- LDWY $3.12
- PPBT $0.53
- 52 Week High
- LDWY $6.19
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- LDWY 46.08
- PPBT 28.34
- Support Level
- LDWY $4.69
- PPBT $0.56
- Resistance Level
- LDWY $5.02
- PPBT $0.66
- Average True Range (ATR)
- LDWY 0.22
- PPBT 0.04
- MACD
- LDWY -0.02
- PPBT 0.06
- Stochastic Oscillator
- LDWY 31.87
- PPBT 44.32
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.